Amador Bioscience
ActiveSummary
The computed 12-month bankruptcy probability of Amador Bioscience is 2.0% (moderate). The 2024 annual accounts show negative equity (-€2.6m) and a net result of -€899,719. Equity is shrinking by ~60.8% per year across the filed fiscal years. The company has been active since 2022 and the Belgian State Gazette contains no insolvency or warning signals.
Checked score
Score 2024
Axes · tick = 2023
Profitability0=
Solvency0=
Growth32=
Track record94
Bankruptcy probability, 12 months
2.0%
Moderate
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.12 against 0.08 in 2023; short-term debt: 665.7% and cash: 29.9% of total assets), and equity is negative.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Four signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Limited track record
This company has not been active as long as an established one and statistically fails somewhat more often.
KBO · incorporation dateAge against the risk zone
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2024Solvency, return and age of the figures
Solvency
-569.1%
Return on assets
-197.2%
Age of the figures
21 mo
lowers risk · Lower-failure-rate sector
In this sector companies fail less often than the Belgian average.
Gazette · bankruptcies per sector, NACE 72
Relative position
BE, all sectors
reference
Scientific research and development (NACE 72)
about 30% fewer bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 21-06-2026, 40 days ahead of the deadline.
NBB · 4 filingsDeviation from the deadline
2025
40 d early
2024
305 d late
2023
63 d late
2022
429 d late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 4 accounts on average 189 days after the deadline; the sector median for financial year 2024 is 13 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 1 February (3 of the last 4 filed years within 225 days of that day).
Companies Code · seven monthsPosition in the running window
30-09-2026 today31-12-2026 close31-07-2027 deadline
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, micro schema
Equity
-€2.6m▼ 53.0%
2023 · -€1.7m
Total assets
€456,270▲ 75.6%
2023 · €259,791
Net result
-€899,719▲ 22.8%
2023 · -€1.2m
Working capital
-€2.7m▼ 49.7%
2023 · -€1.8m
Trend over the years
Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings. Dashed line: the median.
Every figure with its change against the fiscal year before
favourable
unfavourable
Line202220232024
Operating result-€628,957--€1.2m▼ 84.2%-€895,179▲ 22.7%
Net result-€632,406below the sector's middle half--€1.2mbelow the sector's middle half▼ 84.2%-€899,719below the sector's middle half▲ 22.8%
Equity-€532,406below the sector's middle half--€1.7mbelow the sector's middle half▼ 219%-€2.6mbelow the sector's middle half▼ 53.0%
Total assets€267,849below the sector's middle half-€259,791below the sector's middle half▼ 3.0%€456,270within the sector's middle half▲ 75.6%
Debt€800,254-€2.0m▲ 145%€3.1m▲ 56.0%
Working capital-€638,416below the sector's middle half--€1.8mbelow the sector's middle half▼ 179%-€2.7mbelow the sector's middle half▼ 49.7%
Solvency-198.8%below the sector's middle half--653.3%below the sector's middle half▼ 454.5pp-569.1%below the sector's middle half▲ 84.1pp
Current ratio0.20below the sector's middle half-0.08below the sector's middle half▼ 0.120.12below the sector's middle half▲ 0.04
Return on assets (ROA)-236.1%below the sector's middle half--448.3%below the sector's middle half▼ 212.2pp-197.2%below the sector's middle half▲ 251.1pp
Staff (FTE)4.7within the sector's middle half-8.6within the sector's middle half▲ 83.0%
above
within
below
the middle half (P25 to P75) of NACE 72, Scientific research and development, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €895,179 in 2024 against €1.2m in 2023; the loss shrinks.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €456,270
Fixed assets
€85,905 ▼ 14.4%
Current assets
€370,365 ▲ 132%
Key figures and ratios
EBITDA
-€879,827▲
2023 · -€1.1m
Cash flow
-€884,366▲
2023 · -€1.1m
Debt to equity
-1.18▼
2023 · -1.15
Interest coverage
-214.14▼
2023 · -180.71
Debt ≤ 1 year
€3.0m▲
2023 · €1.9m
Income taxes
€431▲
2023 · €148
Staff costs
€594,757▼
2023 · €734,597
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 490 companies that looked in July 2024 the way this one looks now, 6.7% went bankrupt within 24 months and 89% are still going.
- Small
- 2 to 5 years old
- negative equity
- a loss of 10% of the balance sheet or more
6.7%
went bankrupt
3.9%
stopped otherwise
89%
still going
A further 0.6% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 2.0% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 490 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Remuneration, social security and pensions62 | €457,412 | €734,597 | €594,757 | ▼ 19.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €7,452 | €15,353 | €15,353 | = |
| Other operating charges640/8 | €1,359 | €2,830 | €4,508 | ▲ 59.3% |
| Non-recurring operating charges66A | - | €50,000 | €79,008 | ▲ 58.0% |
| Gross operating margin9900 | -€162,734 | -€355,449 | -€201,554 | ▲ 43.3% |
| Operating profit (loss)9901 | -€628,957 | -€1.2m | -€895,179 | ▲ 22.7% |
| Financial income75/76B | €72 | €0 | €1 | ▲ 294% |
| Recurring financial income75 | €72 | €0 | €1 | ▲ 294% |
| Financial charges65/66B | €3,227 | €6,324 | €4,109 | ▼ 35.0% |
| Recurring financial charges65 | €3,227 | €6,324 | €4,109 | ▼ 35.0% |
| Profit (loss) for the period before taxes9903 | -€632,111 | -€1.2m | -€899,288 | ▲ 22.8% |
| Income taxes67/77 | €295 | €148 | €431 | ▲ 191% |
| Profit (loss) for the period9904 | -€632,406 | -€1.2m | -€899,719 | ▲ 22.8% |
| Profit (loss) for the period to be appropriated9905 | -€632,406 | -€1.2m | -€899,719 | ▲ 22.8% |
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Assets | ||||
| Total assets20/58 | €267,849 | €259,791 | €456,270 | ▲ 75.6% |
| Fixed assets21/28 | €106,920 | €100,357 | €85,905 | ▼ 14.4% |
| Tangible fixed assets22/27 | €69,920 | €63,357 | €48,005 | ▼ 24.2% |
| Furniture and vehicles24 | €54,899 | €49,962 | €36,234 | ▼ 27.5% |
| Other tangible fixed assets26 | €15,020 | €13,396 | €11,771 | ▼ 12.1% |
| Financial fixed assets28 | €37,000 | €37,000 | €37,900 | ▲ 2.4% |
| Current assets29/58 | €160,929 | €159,434 | €370,365 | ▲ 132% |
| Amounts receivable within one year40/41 | €60,192 | €153,965 | €231,465 | ▲ 50.3% |
| Trade receivables40 | €18,393 | €62,478 | €139,978 | ▲ 124% |
| Other amounts receivable41 | €41,799 | €91,487 | €91,487 | = |
| Cash at bank and in hand54/58 | €100,737 | €4,983 | €136,648 | ▲ 2,642% |
| Deferred charges and accrued income490/1 | - | €487 | €2,252 | ▲ 363% |
| Equity and liabilities | ||||
| Total equity and liabilities10/49 | €267,849 | €259,791 | €456,270 | ▲ 75.6% |
| Equity10/15 | -€532,406 | -€1.7m | -€2.6m | ▼ 53.0% |
| Contributions10/11 | €100,000 | €100,000 | €100,000 | = |
| Profit (loss) carried forward14 | -€632,406 | -€1.8m | -€2.7m | ▼ 50.1% |
| Amounts payable17/49 | €800,254 | €2.0m | €3.1m | ▲ 56.0% |
| Amounts payable within one year42/48 | €799,345 | €1.9m | €3.0m | ▲ 56.5% |
| Trade debts44 | €20,925 | €88,713 | €68,445 | ▼ 22.8% |
| Suppliers440/4 | €20,925 | €88,713 | €68,445 | ▼ 22.8% |
| Taxes, remuneration and social security45 | €91,421 | €109,023 | €219,740 | ▲ 102% |
| Taxes450/3 | €13,005 | €18,490 | €109,209 | ▲ 491% |
| Remuneration and social security454/9 | €78,416 | €90,533 | €110,531 | ▲ 22.1% |
| Other amounts payable47/48 | €687,000 | €1.7m | €2.7m | ▲ 57.7% |
| Accrued charges and deferred income492/3 | €909 | €15,485 | €15,485 | = |
| Line | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|
| Profit (loss) for the period9904 | -€632,406 | -€1.2m | -€899,719 | ▲ 22.8% |
| + Depreciation and write-downs630 | €7,452 | €15,353 | €15,353 | = |
| Operating cash flow (approximation) | -€624,954 | -€1.1m | -€884,366 | ▲ 23.1% |
| Investment in fixed assets (approximation) | - | -€8,790 | -€900 | ▲ 89.8% |
| Change in cash | - | -€95,754 | €131,665 | ▲ 238% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
30-07
State Gazette act
Resignations: Otilia Lillin (non-statutory director) and Chen Xiaomin (day-to-day manager)7 facts ▸
State Gazette act
Resignations: Otilia Lillin (non-statutory director) and Chen Xiaomin (day-to-day manager)
7 facts ▸
- General meeting, 03-07-2026
- Director resignation, Otilia Lillin (non-statutory director)
- Board meeting, 03-07-2026
- General meeting, 03-07-2026
- Board meeting, 30-06-2026
- Director resignation, Otilia Lillin (day-to-day manager)
- Director resignation, Chen Xiaomin (day-to-day manager)
21-06
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
01-06
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 305 days late
2024
02-10
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 63 days late
02-10
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema · 429 days late
2023
31-12
Financial
Weakest financial yearnet -€1.2m
Net result drops to -€1.2m, the lowest in the series; recovery starts the following year.
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
1 of 6 acts read
About the unread acts
Of the 6 Belgian State Gazette acts we know for this company, 1 has been read. The other 5 have not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
no sitting director, last change in 2026
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
Not every act has been read: a resignation may be missing here
5 of this company's 6 Belgian State Gazette acts have not been read yet. Appointments and resignations recorded in them are missing above: a director who resigned there may therefore still show here as sitting. The acts are in the Timeline.
Location & real-estate footprint
Registered office, Hasselt · 1 establishment unit since 2022
Ground area
3.4 ha
Building footprint
3,971 m²
Volume, LiDAR
15,572 m³
2 parcels, Flanders · tallest building 20.9 m, ±4 floors. Linked by address, not a title deed.
181
companies at this address
See who is registered here
1 establishment unit
Amador Bioscience
since 20222.328.347.220
2 parcels
Flanders
2
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 71322A0540/00G003 | Flanders | 2.9 ha | 1 · 2,491 m² | 2.6 m |
| 71326F0010/00C003 | Flanders | 5,413 m² | 1 · 1,479 m² | 20.9 m · 4 fl. |
Linked by address, not proof of ownership
Good to know
2 of 2 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Mandate history
2 people since 2026, 0 in office
- Board
- Day-to-day management
- began earlier
| Name | Functions and periods |
|---|---|
| Chen Xiaomin |
|
| Otilia LILLIN |
|
Similar companies · same sector and region
Hammerhead Bio
BE 1042.253.914
Hasselt
ALIGOS BELGIUM
BE 0702.969.886
Leuven
Alixar
BE 0693.937.307
Hasselt
ANEUROTECH
BE 0785.263.993
Alken
ARCHER RESEARCH
BE 0538.648.522
Diepenbeek
This company's figures show no positive equity and no headcount, so a size comparison is not possible. These companies share only the sector and the region. Of 762 companies in sector 72101 we hold annual accounts for 484. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded11-01-2022
Fiscal year end31-12
Activities, NACEBEL 2025
72101Research and development on biotechnology
62900Other information technology and computer services
72109Other research and development on natural sciences
74999Other professional, scientific and technical activities
E-invoicing
Reachable via Peppol
Peppol ID
0208:0779966013
Registered
07-05-2026
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.